Berho M, Viciana A L, Poppiti R J, Ruiz P
Rywlin Department of Pathology, Mount Sinai Medical Center, Miami, USA.
J Fla Med Assoc. 1997 Feb;84(2):104-10.
Breast cancer treatment remains a controversial and challenging issue. Treatment of this disease is often guided by the clinical stage and type of tumor present, as well as information provided by a variety of prognostic indicators which can be employed. DNA analysis by flow cytometry is a relatively new technique that is emerging as a powerful tool to predict the biologic behavior of breast tumors. A majority of studies have demonstrated that the S-phase fraction measured by DNA flow cytometric is an independent predictor of patient outcome. There is less conclusive information regarding the association of DNA ploidy with the clinical behavior of breast malignancies, although, tumor grading often closely parallels this DNA parameter. New flow cytometry methodology involves multiparameter analysis that allows a simultaneous examination of DNA ploidy and cell cycle analysis with surface or internal molecules. This newer approach permits a precise delineation of DNA characteristics in distinct cell populations within a tumor and will likely enhance the utility of this procedure in determining the biologic behavior of the breast tumor.
乳腺癌治疗仍然是一个有争议且具有挑战性的问题。这种疾病的治疗通常由肿瘤的临床分期和类型以及各种可用的预后指标所提供的信息来指导。通过流式细胞术进行DNA分析是一种相对较新的技术，正逐渐成为预测乳腺肿瘤生物学行为的有力工具。大多数研究表明，通过DNA流式细胞术测量的S期分数是患者预后的独立预测指标。关于DNA倍性与乳腺恶性肿瘤临床行为之间的关联，确定性信息较少，尽管肿瘤分级通常与这个DNA参数密切相关。新的流式细胞术方法涉及多参数分析，它允许同时检查DNA倍性以及通过表面或内部分子进行细胞周期分析。这种更新的方法能够精确描绘肿瘤内不同细胞群体的DNA特征，并且可能会提高该方法在确定乳腺肿瘤生物学行为方面的实用性。
